When tested in a murine modelof type 2 diabetes, 19a improved glucose tolerance andreduced plasma levels of insulin, triglycerides, and cholesterol.164 Remarkably, 19b reduced the recruitmentof SIRT6 to DNA-damage locations and sensitized primary MM cells,along with melphalan- and doxorubicin-resistant MM cell lines, toDNA-damaging chemotherapeutics.165 Compound 19b also decreased the viability of DLBCL cells, usually displayingSIRT6 overexpression, and inhibited their proliferation in a time-and dose-dependent fashion, through induction of apoptosis and cellcycle arrest at G2/M phase. The gene discussed is SIRT6; the disease is Miyoshi myopathy.